甘精胰岛素市场，按类型，按糖尿病类型，按配销通路，按地理

Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Geography

出版日期: 2024年03月20日 | 出版商:

Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年全球甘精胰岛素市值为54.5亿美元，预计到2031年将达84.3亿美元，2024年至2031年年复合成长率(CAGR)为6.4%。

报告范围		报告详情
基准年：	2023年	2023/2024 年市场规模：	54.5 亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测期间 2023/2024 至 2030/2031 年复合成长率：	6.40%	2030/2031 价值预测：	84.3 亿美元

甘精胰岛素市占率 (%)，按地区，2024 年

甘精胰岛素，也称为来得时，是一种长效基础胰岛素，用于治疗糖尿病。它是透过重组 DNA 技术製造的人类胰岛素的合成形式，经过改造可溶于酸性环境。注射后，它在皮下组织中沉淀并形成微晶体，形成一个储存库，胰岛素逐渐被吸收到血液中。这种延长的释放和作用持续时间允许每日一次给药，以帮助第 1 型和第 2 型糖尿病患者在 24 小时内控制血糖值。与其他基础胰岛素（例如地特胰岛素和 NPH 胰岛素）相比，甘精胰岛素的吸收速度较慢，因此可以在血液中提供平稳且一致的胰岛素水平。

市场动态：

全球甘精胰岛素市场的成长是由全球糖尿病盛行率不断上升所推动的。根据国际糖尿病联盟2021 的估计，2021 年将有超过5.37 亿成年人患有糖尿病，预计到2030 年这一数字将增至6.43 亿，到2045 年将增至7.83 亿。市场成长，因为糖尿病对糖尿病的影响较大。然而，成本限制，尤其是在发展中国家，是一种限制。从积极的一面来看，持续开发更有效、更方便的药物输送技术预计将带来新的机会。

研究的主要特点：

该报告对全球甘精胰岛素市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数描述了全球甘精胰岛素市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球甘精胰岛素市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球甘精胰岛素市场的各种策略矩阵轻鬆做出决策。

Report Coverage	Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 5.45 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	6.40%	2030/2031 Value Projection:	US$ 8.43 Bn

Insulin glargine, also known as Lantus, is a long-acting basal insulin that is used for the treatment of diabetes mellitus. It is a synthetic form of human insulin created through recombinant DNA technology, engineered to be soluble in acidic environments. Upon injection, it precipitates and forms microcrystals in the subcutaneous tissue, creating a depot from which insulin is gradually absorbed into the bloodstream. This extended release and duration of action profile allows once-daily dosing to help control blood glucose levels in patients with type 1 and type 2 diabetes over 24 hours. Insulin glargine has a slower absorption profile as compared to other basal insulins such as insulin detemir and insulin NPH, and thus, provides a smooth and consistent level of insulin in the blood.

Market Dynamics:

Global insulin glargine market growth is driven by growing prevalence of diabetes worldwide. According to estimates by the International Diabetes Federation 2021, over 537 million adults lived with diabetes in 2021, and the number is projected to rise to 643 million by 2030 and 783 million by 2045. Increasing geriatric population also contributes to market growth since diabetes is more common in older age groups. However, cost constraints, especially in developing countries, acts as a restrain. On the positive side, ongoing development of more effective and convenient drug delivery technologies is expected to present new opportunities.

Key Features of the Study:

This report provides in-depth analysis of the global insulin glargine market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global insulin glargine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Sanofi, Biocon, Eli Lilly and Company, Boehringer Ingelheim, Gan & Lee, Kalbe Pharma, Polus Biopharm, Samsung Bioepis, Wockhardt, Novo Nordisk AS, Julphar, and Viatris Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
Global insulin glargine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin glargine market.

Detailed Segmentation

Type:
- Lantus
- Basaglar
- Toujeo
- Soliqua/Suliqua
- Others
Diabetes Type:
- Type 2 Diabetes
- Type 1 Diabetes
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Company Profiles:
- Sanofi
- Biocon
- Eli Lilly and Company
- Boehringer Ingelheim
- Gan & Lee
- Kalbe Pharma
- Polus Biopharm
- Samsung Bioepis
- Wockhardt
- Novo Nordisk AS
- Julphar
- Viatris Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Diabetes Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing prevalence of diabetes worldwide
- High cost of insulin glargine
- Increase in awareness about diabetes management
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Insulin Glargine Market- Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Insulin Glargine Market, By Type, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Lantus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Basaglar
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Toujeo
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Soliqua/Suliqua
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Insulin Glargine Market, By Diabetes Type, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Insulin Glargine Market, By Distribution Channel, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Insulin Glargine Market, By Region, 2019-2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
North America
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
U.K.
Germany
Italy
France
Spain
Russia
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Diabetes Type, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Gan & Lee
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Kalbe Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Polus Biopharm
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Samsung Bioepis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novo Nordisk AS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Julphar
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies